0001209191-21-065839.txt : 20211119
0001209191-21-065839.hdr.sgml : 20211119
20211119165920
ACCESSION NUMBER: 0001209191-21-065839
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211117
FILED AS OF DATE: 20211119
DATE AS OF CHANGE: 20211119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ROBINS HARLAN S
CENTRAL INDEX KEY: 0001780851
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 211429072
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-17
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780851
ROBINS HARLAN S
1165 EASTLAKE AVENUE E
SEATTLE
WA
98109
0
1
0
0
Chief Scientific Officer
Common Stock
2021-11-17
4
M
0
3700
6.55
A
73060
D
Common Stock
2021-11-17
4
S
0
3700
32.05
D
69360
D
Common Stock
2021-11-18
4
M
0
300
6.55
A
69660
D
Common Stock
2021-11-18
4
S
0
300
31.36
D
69360
D
Stock Option (Right to Buy)
6.55
2021-11-17
4
M
0
3700
0.00
D
2028-02-07
Common Stock
3700
285100
D
Stock Option (Right to Buy)
6.55
2021-11-18
4
M
0
300
0.00
D
2028-02-07
Common Stock
300
284800
D
These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2021.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.45 to 32.36, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.00 to 31.76, inclusive.
The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Harlan Robins by Eric Billings, Attorney-in-Fact
2021-11-19